vs
Side-by-side financial comparison of Prime Medicine, Inc. (PRME) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
Prime Medicine, Inc. is the larger business by last-quarter revenue ($838.0K vs $240.0K, roughly 3.5× Vir Biotechnology, Inc.). Prime Medicine, Inc. runs the higher net margin — -5498.7% vs -67975.4%, a 62476.7% gap on every dollar of revenue. On growth, Prime Medicine, Inc. posted the faster year-over-year revenue change (-61.6% vs -89.9%). Prime Medicine, Inc. produced more free cash flow last quarter ($-37.5M vs $-167.9M).
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
PRME vs VIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0K | $240.0K |
| Net Profit | $-46.1M | $-163.1M |
| Gross Margin | — | — |
| Operating Margin | -5800.5% | -72267.9% |
| Net Margin | -5498.7% | -67975.4% |
| Revenue YoY | -61.6% | -89.9% |
| Net Profit YoY | -9.0% | 23.7% |
| EPS (diluted) | $-0.22 | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $838.0K | — | ||
| Q3 25 | $1.2M | $240.0K | ||
| Q2 25 | $1.1M | $1.2M | ||
| Q1 25 | $1.5M | $3.0M | ||
| Q4 24 | $2.2M | $12.4M | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | $0 | $3.1M | ||
| Q1 24 | $591.0K | $56.4M |
| Q4 25 | $-46.1M | — | ||
| Q3 25 | $-50.6M | $-163.1M | ||
| Q2 25 | $-52.6M | $-111.0M | ||
| Q1 25 | $-51.9M | $-121.0M | ||
| Q4 24 | $-42.3M | — | ||
| Q3 24 | — | $-213.7M | ||
| Q2 24 | $-55.3M | $-138.4M | ||
| Q1 24 | $-45.8M | $-65.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 97.9% | ||
| Q2 24 | — | 98.3% | ||
| Q1 24 | — | 99.9% |
| Q4 25 | -5800.5% | — | ||
| Q3 25 | -4406.0% | -72267.9% | ||
| Q2 25 | -4787.2% | -9754.3% | ||
| Q1 25 | -3603.3% | -4602.5% | ||
| Q4 24 | -2025.7% | — | ||
| Q3 24 | — | -9718.7% | ||
| Q2 24 | — | -5158.7% | ||
| Q1 24 | -8179.5% | -142.0% |
| Q4 25 | -5498.7% | — | ||
| Q3 25 | -4129.1% | -67975.4% | ||
| Q2 25 | -4716.7% | -9139.9% | ||
| Q1 25 | -3568.8% | -3989.6% | ||
| Q4 24 | -1936.6% | — | ||
| Q3 24 | — | -8979.7% | ||
| Q2 24 | — | -4500.1% | ||
| Q1 24 | -7743.0% | -115.8% |
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.32 | $-1.17 | ||
| Q2 25 | $-0.41 | $-0.80 | ||
| Q1 25 | $-0.40 | $-0.88 | ||
| Q4 24 | $-0.31 | — | ||
| Q3 24 | — | $-1.56 | ||
| Q2 24 | $-0.46 | $-1.02 | ||
| Q1 24 | $-0.44 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.0M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $120.9M | $796.1M |
| Total Assets | $342.7M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.0M | — | ||
| Q3 25 | $71.4M | $497.8M | ||
| Q2 25 | $53.8M | $598.7M | ||
| Q1 25 | $91.9M | $790.9M | ||
| Q4 24 | $182.5M | $901.0M | ||
| Q3 24 | — | $909.0M | ||
| Q2 24 | $55.6M | $1.1B | ||
| Q1 24 | $94.2M | $1.1B |
| Q4 25 | $120.9M | — | ||
| Q3 25 | $161.8M | $796.1M | ||
| Q2 25 | $60.9M | $947.5M | ||
| Q1 25 | $106.9M | $1.0B | ||
| Q4 24 | $153.1M | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $196.6M | $1.4B | ||
| Q1 24 | $243.8M | $1.5B |
| Q4 25 | $342.7M | — | ||
| Q3 25 | $385.0M | $1.0B | ||
| Q2 25 | $279.0M | $1.2B | ||
| Q1 25 | $328.2M | $1.3B | ||
| Q4 24 | $297.5M | $1.4B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $259.7M | $1.7B | ||
| Q1 24 | $311.4M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.3M | $-167.6M |
| Free Cash FlowOCF − Capex | $-37.5M | $-167.9M |
| FCF MarginFCF / Revenue | -4480.4% | -69952.9% |
| Capex IntensityCapex / Revenue | 34.6% | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-167.1M | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-37.3M | — | ||
| Q3 25 | $-35.0M | $-167.6M | ||
| Q2 25 | $-41.4M | $-120.2M | ||
| Q1 25 | $-48.9M | $-78.1M | ||
| Q4 24 | $16.2M | $-446.4M | ||
| Q3 24 | — | $-171.5M | ||
| Q2 24 | $-45.5M | $-77.8M | ||
| Q1 24 | $-67.7M | $-109.4M |
| Q4 25 | $-37.5M | — | ||
| Q3 25 | $-35.3M | $-167.9M | ||
| Q2 25 | $-43.0M | $-122.8M | ||
| Q1 25 | $-51.3M | $-79.7M | ||
| Q4 24 | $14.5M | $-453.7M | ||
| Q3 24 | — | $-174.2M | ||
| Q2 24 | $-47.4M | $-78.5M | ||
| Q1 24 | $-70.0M | $-111.3M |
| Q4 25 | -4480.4% | — | ||
| Q3 25 | -2880.5% | -69952.9% | ||
| Q2 25 | -3855.1% | -10111.8% | ||
| Q1 25 | -3526.8% | -2630.1% | ||
| Q4 24 | 662.1% | -3666.2% | ||
| Q3 24 | — | -7321.3% | ||
| Q2 24 | — | -2553.3% | ||
| Q1 24 | -11849.6% | -197.4% |
| Q4 25 | 34.6% | — | ||
| Q3 25 | 20.2% | 132.1% | ||
| Q2 25 | 141.0% | 209.1% | ||
| Q1 25 | 166.6% | 53.7% | ||
| Q4 24 | 82.0% | 59.0% | ||
| Q3 24 | — | 116.3% | ||
| Q2 24 | — | 21.7% | ||
| Q1 24 | 393.2% | 3.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
